Trends and disparities in mortality from malignant neoplasms of male genital organs in the United States, 1999–2023.

11134 Background: Genital malignant neoplasms remain an important cause of mortality among males living in the United States. Tumor progression and organ-specific compromise contribute to increased risk and disease severity. Although recent data show overall declines in mortality over time, disparities persist, highlighting the need to analyze and interpret trends across demographic and geographic factors. Methods: The mortality data from the CDC WONDER underlying cause of death files for men aged ≥25 years were used to analyze age-adjusted and crude mortality rates (AAMRs and CMRs) per 100,000 for male genital neoplasms (ICD-10 Codes: C60-C63.9), stratified by year, gender, race/ethnicity, place of death, and geography. Joinpoint regression was used to estimate average annual percent change (AAPC) and annual percent change (APC) with 95% confidence intervals (CIs). Statistical significance was defined as p<0.05. Results: From 1999 to 2023, a total of 765,516 deaths were reported among patients of male genital malignant neoplasms, with most occurring at the decedent’s home. The overall AAMR decreased from 18.29 in 1999 to 12.51 in 2023 (AAPC: -1.55; 95% CI: -1.71 to -1.39; p<0.001), with the most significant decline observed between 1999–2013 (APC: -2.73; p<0.001). Men aged 65 years and older experienced the greatest annual decline (-2.50%; p<0.001), but had the highest CMR (63.84), whereas mortality among men aged 25–44 years increased notably between 2013–2023 (APC: 3.65; p<0.001). The highest AAMR was observed among non-Hispanic (NH) Blacks (26.98), while the lowest AAMR was noted among NH Asians (6.30). Geographic disparities were evident, with the West having the highest AAMR (14.48) and the Northeast having the lowest (13.02). Non-metropolitan areas showed a higher AAMR (14.94 vs 13.79) and a slightly steeper decline in mortality than non-metropolitan areas (AAPC: -1.81 vs -1.80). At the state level, the District of Columbia ranked the highest, placed in the top 90th percentile, between 1999 and 2023. Conclusions: Despite a significant decline in mortality related to malignant neoplasms of male genitals over the past two decades, disparities persist, especially among older men, NH Black individuals, those living in non-metropolitan areas, and the West region. This underscores the need for targeted prevention, early detection, and equitable integrated care. Average annual percent change (AAPC) of age-adjusted mortality rates for male genital malignant neoplasms in the United States, 1999 to 2023. Variable Deaths AAPC (95%CI) Overall (Male) 765,516 -1.55 (-1.71 to -1.39) Non-metropolitan areas 126,009 -1.80 (-2.05 to -1.55) Metropolitan areas 537,718 -1.81 (-2.00 to -1.62)